208 related articles for article (PubMed ID: 8251891)
41. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
42. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
[TBL] [Abstract][Full Text] [Related]
43. CML: new biologic therapies, endpoints and questions.
Martin A; Cheson BD
Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
[No Abstract] [Full Text] [Related]
44. Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.
Mahé B; Gaillard F; Labadie F; Papin S; Letortorec S; Moreau P; Harousseau JL; Milpied N
Leuk Lymphoma; 1995 Nov; 19(5-6):515-7. PubMed ID: 8590856
[TBL] [Abstract][Full Text] [Related]
45. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Aviles A; Duque G; Talavera A; Guzman R
Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
[TBL] [Abstract][Full Text] [Related]
46. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Talpaz M; Kantarjian HM; O'Brien S; Kurzrock R
Baillieres Clin Haematol; 1997 Jun; 10(2):291-305. PubMed ID: 9376665
[No Abstract] [Full Text] [Related]
47. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Jehn U; Pötscher C; Heinemann V
Leuk Lymphoma; 1995 Sep; 19(1-2):153-7. PubMed ID: 8574162
[TBL] [Abstract][Full Text] [Related]
48. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
[TBL] [Abstract][Full Text] [Related]
49. Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
Rosti G; De Vivo A; Zuffa E; Baccarani M
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S11-3. PubMed ID: 8769692
[TBL] [Abstract][Full Text] [Related]
50. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
51. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
Ezaki K
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
[No Abstract] [Full Text] [Related]
52. Optimizing treatment for chronic myeloid leukemia.
Goldman JM
N Engl J Med; 1997 Jul; 337(4):270-1. PubMed ID: 9227935
[No Abstract] [Full Text] [Related]
53. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
54. Treatment of myelogenous leukemia: current status and investigational options.
Kantarjian HM; O'Brien S; Anderlini P; Talpaz M
Blood; 1996 Apr; 87(8):3069-81. PubMed ID: 8605319
[No Abstract] [Full Text] [Related]
55. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
[TBL] [Abstract][Full Text] [Related]
56. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
[TBL] [Abstract][Full Text] [Related]
57. Chronic myelogenous leukemia: does interferon alpha prolong life?
Hehlmann R
Leukemia; 1996 Feb; 10(2):193-6. PubMed ID: 8637225
[No Abstract] [Full Text] [Related]
58. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
59. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
[TBL] [Abstract][Full Text] [Related]
60. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
